The abstract is read at the publisher; the summary is JClub's.
Cell surface RNA-binding proteins with cell-type and disease-specific localization are emerging as potential biomarker and immunotherapy targets across cancers and other diseases.
- Why it matters: RBPs regulate RNA metabolism and non-coding RNA function, shaping cell identity and contributing to disease, but druggable targets and therapeutic entry points remain incompletely mapped.
- What they did: The work reviews intracellular RBP functions and disease links, then surveys the nascent field of cell surface RBPs and outlines strategies to exploit their localization for immunotherapeutic design.
- The result: By integrating established intracellular roles with emerging cell surface evidence, it highlights how cell surface RBPs may enable biomarker discovery and immunotherapy development in multiple disease contexts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.